alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Drug trials: efficacy and safety

902 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Identifying and Treating Insomnia in Patients Living With Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. The Journal of clinical psychiatry 2020-04-21 Risk factors

    The number of patients with Alzheimer's disease (AD) is increasing significantly.

  2. Lemborexant: First Approval

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Drugs 2020-03 Risk factors

    Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia.

  3. Natural and synthetic drugs used for the treatment of the dementia

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Biochemical and biophysical research communications 2020-02-07 Treatments

    This review is devoted to comparative pharmacological analysis of synthetic drugs such as memantine and its isomers, as well as tacrine, velnacrine, rivastigmine, and donepezil, with natural alkaloids, terpenoids, and triterpenoid peroxides, which are used to treat dementia, Alzheimer's and Parkinson's diseases, myasthenia gravis and other neurodegenerative diseases.

  4. Therapy for Insomnia and Circadian Rhythm Disorder in Alzheimer Disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Current treatment options in neurology 2020-02-05 Risk factors

    RECENT FINDINGS: Some studies investigated the efficacy and safety of hypnotic agents as ramelteon and mirtazapine to treat sleep disorders in AD but no significant therapeutic effects have been observed.

  5. Cholinesterase as a Target for Drug Development in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Methods in molecular biology (Clifton, N.J.) 2020 Treatments

    Alzheimer's disease (AD) is an enormous healthcare challenge, and 50 million people are currently suffering from it.

  6. Transdermal Drug Delivery Systems and their Potential in Alzheimer's Disease Management

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. CNS & neurological disorders drug targets 2020 Treatments

    Alzheimer's disease is a neuropathological disease with symptoms such as language problems, confusion as to place or time, loss of interest in activities, which were previously enjoyed, behavioral changes, and memory loss.

  7. Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Alzheimer's disease : JAD 2020 Drug development

    Although more than 100 years have passed since Alois Alzheimer reported a case of Alzheimer's disease (AD), a definitive answer to the causes of cognitive impairment in the disease remains elusive.

  8. Correlation Between Donepezil and QTc Prolongation and Torsades de Pointes: A Very Rare Phenomenon

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Cureus 2019-12-23 Treatments

    Dementia can be seen as a clinical syndrome featuring a decline in cognitive and psychological abilities that can cause disability.

  9. A contemporary review of obstructive sleep apnea

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Current opinion in pulmonary medicine 2019-11 Risk factors

    Decreased sleep time in the elderly is a precipitating factor in amyloid retention.

  10. Insights into Computational Drug Repurposing for Neurodegenerative Disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Trends in pharmacological sciences 2019-07-17 Drug development

    Computational drug repurposing has the ability to remarkably reduce drug development time and cost in an era where these factors are prohibitively high.

  11. Approach Toward Diabetes Treatment in the Elderly

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Sisli Etfal Hastanesi tip bulteni 2019-06-25 Drug development

    Concomitant diseases in elderly individuals with diabetes (renal failure, heart failure, ischemic heart disease, stroke, urinary incontinence, cognitive impairment, dementia, sarcopenia, and osteoporosis) make diabetes management difficult.

  12. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Current pharmaceutical design 2019 Treatments

    In the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters.

  13. A Review for Lithium: Pharmacokinetics, Drug Design, and Toxicity

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. CNS & neurological disorders drug targets 2019 Drug development

    Lithium as a mood stabilizer has been used as the standard pharmacological treatment for Bipolar Disorder (BD) for more than 60 years.

  14. The exploration of novel Alzheimer's therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018-12-03 Drug development

    Novel drug development is onerous, time consuming and overpriced process with particularly low success and relatively high enfeebling rates.

  15. Repurposing Proteostasis-Modifying Drugs to Prevent or Treat Age-Related Dementia: A Systematic Review

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in physiology 2018-10-30 Drug development

    Overall 47 trials, 38 animal and 9 human, were isolated for inclusion in this review.

  16. Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Clinical interventions in aging 2018-10-11 Treatments

    Donepezil, an acetylcholinesterase inhibitor (AChEI), has been widely used to treat Alzheimer's disease (AD) in China.

  17. A molecular approach in drug development for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018-07-11 Treatments

    An increase in dementia numbers and global trends in population aging across the world prompts the need for new medications to treat the complex biological dysfunctions, such as neurodegeneration associated with dementia.

  18. [Late life depression - Diagnosis, pathophysiology and therapeutic strategies]

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Fortschritte der Neurologie-Psychiatrie 2018-04-24 Risk factors

    Late-life depression is a frequent and severe mental disorder.

  19. Advances in Pharmacotherapy of Late-Life Depression

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Current psychiatry reports 2018-04-07 Risk factors

    We then review new research on moderators of clinical response and how to use the information for improved efficacy.

  20. Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood⁻Brain Barrier

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Biomimetics (Basel, Switzerland) 2018-03-07 Vascular contributions

    Over the past decades, a frequent co-morbidity of cerebrovascular pathology and Alzheimer's disease has been observed.

  21. Hearing Loss in the Elderly

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Clinics in geriatric medicine 2018-02-14 Risk factors

    Presbycusis, or age-related hearing loss (ARHL), is the result of physiologic and pathologic changes associated with advancing age.

  22. Atypical Antipsychotics in Late-Life and Treatment-Resistant Depression

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 2018-02-01 Risk factors

    As persons age, their risk of developing late-life depression increases.

  23. France Will No More Reimburse Available Symptomatic Drugs Against Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Alzheimer's disease : JAD 2018 Treatments

    The French Minister of Health published a decree on May 29th of 2018 removing the drugs used to fight against symptoms due to Alzheimer's disease (donepezil, rivastigmine, galantamine, memantine) from the list of available reimbursed drugs.

  24. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Expert opinion on biological therapy 2017-10-16 Treatments

    The recent failure of several clinical trials on anti-β-amyloid (Aβ) drugs in Alzheimer's disease (AD) suggested earlier intervention in the disease course.

  25. Dementia risk and prevention by targeting modifiable vascular risk factors

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of neurochemistry 2017-09-06 Prevention trials

    The incidence of dementia is expected to double in the next 20 years and will contribute to heavy social and economic burden.

From across this topic

9 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

Other topics